New shot tested for Tough-to-Treat eczema
NCT ID NCT07445919
Summary
This study is testing a new injectable antibody called SM17 for adults with moderate to severe atopic dermatitis (eczema) that doesn't respond well to standard creams. About 200 participants will receive either SM17 or a placebo shot to see if it safely reduces the severity of their skin rash and itching. The main goal is to find the right dose and see how much it improves eczema symptoms over 16 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
Beijing, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.